Endra Life Sciences Inc. · NASDAQ:NDRA
Endra Life Sciences — Investor Presentation (June 2025)
19 slides from Endra Life Sciences's investor presentation, June 2025
Slide 1: ENDRA Life Sciences
ENDRA Life Sciences New Biomarkers for Metabolic Diseases Detection & Management NASDAQ: NDRA June 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements All statements in this presentation that are not based on historical fact are “forward -looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward -looking statements, which are based
Slide 3: Investment Highlights
Investment Highlights 2B+ $43.3B Global Steatotic Liver Disease (SLD) Patients Global Diagnostic Liver TAM Over 100 million patients in the US alone $17.4B US market; Initial focus on $7.4B US MASLD* diagnostics 84 63% Global Patents Reduced Y-o-Y Operating Cash Burn Proprietary TAEUS® platform tech
Slide 4: What is New ENDRA
What is New ENDRA ENDRA offers an AI-powered solution for measuring liver fat, focusing on GLP-1 therapies with a subscription business model targeting high-end primary care, metabolic specialists, and pharmaceutical companies. Goal & Focus Solution Target Customers Business Model Establish key biom
Slide 5: The Unmet Need
The Unmet Need Steatotic Liver Disease affects billions globally with significant costs, new GLP-1 therapies emerge and current diagnostic methods remain inadequate, as there is no reliable, inexpensive, point-of-care test available to detect and monitor liver fat Global Health Burden Emerging Thera
Slide 6: Our Solution: TAEUS
Our Solution: TAEUS® Thermo-Acoustic (TA) Precise Measurement Robust IP Portfolio Technology uses RF source Quantitative, accurate results 84 global patents issued with with ultrasound reception for delivered at point-of-care 24 pending applications enhanced tissue penetration setting worldwide Auto
Slide 7: TAEUS Liver vs. Competition
TAEUS® Liver vs. Competition Comparison TAEUS MRI Biopsy Premium Handheld Ultrasound Ultrasound Test Accuracy Test Reproducibility Larger Patients Exam Time Radiological Interpretation Cost Point-of-Care 6
Slide 8: Customers: Key Focus Segments - US
Customers: Key Focus Segments - US ENDRA targets four high-growth U.S. market segments with specific value propositions for each, focusing on pharmaceutical research, premium healthcare, and specialized medical facilities with the ultimate goal of penetrating primary care at large Pharma & CROs Conc
Slide 9: Obesity - Primary Risk Factor in Multiple Diseases
Obesity - Primary Risk Factor in Multiple Diseases Obesity is a major risk factor across multiple conditions, driving healthcare costs into hundreds of billions yearly for diab etes, cardiovascular, and liver diseases, while the obesity market itself is projected to grow significantly to $100B+ Type
Slide 10: New Guidelines Driving Behavior
New Guidelines Driving Behavior Major medical organizations are now recognizing the importance of liver fat assessment, updating disease terminology, and recommending early screening, particularly for patients with diabetes or metabolic conditions. New Nomenclature American Diabetes Association Amer
Slide 11: TAEUS LIVER TAM: Liver Diagnostic Market
TAEUS LIVER TAM: Liver Diagnostic Market TAEUS® Liver initial goal - capture 1% of US MASLD market by focusing on specialties benefiting from GLP -1 therapies prescription and management Global Market US Market US MASLD Specific $43.3 Billion1 $17.4 Billion1 $7.4 Billion1 10
Slide 12: Go-To-Market Strategy with TAEUS Liver
Go-To-Market Strategy with TAEUS Liver ENDRA's go-to-market approach focuses on high-value customer segments with a hub-and-spoke sales strategy, leveraging a subscription revenue model to drive adoption and growth. Target major medical networks and pharmaceutical companies to secure initial contrac
Slide 13: TAEUS Liver Market Positioning
TAEUS® Liver Market Positioning 12
Slide 14: TAEUS Strategically Positioned for Multiple Markets
TAEUS Strategically Positioned for Multiple Markets 84 ISSUED PATENTS PATENTS BY APPLICATION % Patents TAM [Global / US] 41 issued in U.S. with strong defensive and TAEUS Liver 65% [$43.3B / $17.4B]1 offensive claims. TAEUS Temp Ablation 20% [$13.2B / $3.1B]2 43 patents issued globally , including 2
Slide 15: Key Milestones & Future Catalysts
K e y M ile s t o n e s & F u t u r e C a t a ly s t s Timeline Q4 2024 H1 2025 H2 2025 H1 2026 Clinical / Regulatory Launch 100+ Complete multi-site Obtain FDA alignment Complete FDA pivotal participant multi-site pilot study for pivotal endpoints trial pilot study Identify 4-6 sites for Launch FDA
Slide 16: Leadership, Board & Advisors
Leadership, Board & Advisors LEADERSHIP TEAM Alexander Tokman Richard Jacroux Michael Thornton CEO & Director CFO CTO 25+ years in medtech; GE Healthcare, 10+ years public companies experience; 25+ years in medtech, Founder of EVS, MicroVision, IUNU, Allen Institute for AI (AI2) Ernst & Young, IUNU,
Slide 17: Positioned for Growth
Positioned for Growth Strategic Pivot Key biomarker for metabolic diseases management via GLP-1 therapies Enhanced Go-to-Market Focus on high-TAM segments Pharma/CRO, Concierge Medicine and Bariatric/Metabolic/Endo clinics with subscription model Reduced Burn Operating cash burn cut by 63% Y-o-Y Str
Slide 18: ENDRA Financial Snapshot
ENDRA Financial Snapshot Results as of April 30, 2025 $2.5M 0 Cash Position Debt Strong liquidity for operations Debt-free balance sheet 738K 919K Common Shares Fully Diluted Shares 17
Slide 19: Sources
Global Market Insights Sources Slide 4: 1 The Lancet: “The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis” | July 2022 2 American Liver Foundation: link 3 “Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging” Jessica K Dyson, Quentin M
ENDRA Life Sciences — Investor Presentation (June 2025) on 6ix